KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Amortization of Deferred Charges: 2014-2024

Historic Amortization of Deferred Charges for Travere Therapeutics (TVTX) over the last 11 years, with Dec 2024 value amounting to $1.7 million.

  • Travere Therapeutics' Amortization of Deferred Charges fell 85.17% to $428,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $1.6 million, marking a year-over-year decrease of 85.57%. This contributed to the annual value of $1.7 million for FY2024, which is 0.41% up from last year.
  • Travere Therapeutics' Amortization of Deferred Charges amounted to $1.7 million in FY2024, which was up 0.41% from $1.7 million recorded in FY2023.
  • Over the past 5 years, Travere Therapeutics' Amortization of Deferred Charges peaked at $11.2 million during FY2021, and registered a low of $1.6 million during FY2022.
  • For the 3-year period, Travere Therapeutics' Amortization of Deferred Charges averaged around $1.7 million, with its median value being $1.7 million (2023).
  • As far as peak fluctuations go, Travere Therapeutics' Amortization of Deferred Charges grew by 7.29% in 2021, and later slumped by 85.57% in 2022.
  • Yearly analysis of 5 years shows Travere Therapeutics' Amortization of Deferred Charges stood at $10.5 million in 2020, then increased by 7.29% to $11.2 million in 2021, then plummeted by 85.57% to $1.6 million in 2022, then increased by 5.92% to $1.7 million in 2023, then rose by 0.41% to $1.7 million in 2024.